LIDDS AB: LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid-formulated docetaxel
UPPSALA, SWEDEN - LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid-docetaxel is low and that the study demonstrated activity in both